Table 3.
Treatment-related adverse events
| TRAEs, n (%) | All patients (N=37) | |
| Any grade | Grade ≥3 | |
| Any TRAE | 37 (100.0) | 30 (81.1) |
| TRAEs leading to camrelizumab discontinuation | 1 (2.7) | 1 (2.7) |
| TRAEs leading to famitinib discontinuation | 3 (8.1) | 2 (5.4) |
| TRAEs leading to camrelizumab interruption | 8 (21.6) | 5 (13.5) |
| TRAEs leading to famitinib interruption | 30 (81.1) | 24 (64.9) |
| TRAEs leading to famitinib dose reduction | 7 (18.9) | 4 (10.8) |
| Treatment-related SAEs | 5 (13.5) | 5 (13.5) |
| Any grade TRAEs occurring in at least 20% of patients | ||
| Neutrophil count decreased | 30 (81.1) | 11 (29.7) |
| White blood cell count decreased | 29 (78.4) | 4 (10.8) |
| Platelet count decreased | 26 (70.3) | 5 (13.5) |
| Hypertension | 24 (64.9) | 12 (32.4) |
| Palmar–plantar erythrodysesthesia syndrome | 21 (56.8) | 2 (5.4) |
| Anemia | 17 (45.9) | 3 (8.1) |
| Proteinuria | 17 (45.9) | 0 |
| Gamma-glutamyltransferase increased | 15 (40.5) | 3 (8.1) |
| Hypertriglyceridemia | 15 (40.5) | 2 (5.4) |
| Hypercholesterolemia | 14 (37.8) | 0 |
| Aspartate aminotransferase increased | 13 (35.1) | 1 (2.7) |
| Alanine aminotransferase increased | 11 (29.7) | 1 (2.7) |
| Diarrhea | 9 (24.3) | 1 (2.7) |
| Occult blood positive | 9 (24.3) | 0 |
| Plateletcrit decreased | 8 (21.6) | 1 (2.7) |
| Weight decreased | 8 (21.6) | 0 |
TRAEs, treatment-related adverse events; SAEs, serious adverse events.